Dermata Therapeutics- Warrants (13/08/2026) Operating Income

As of the most recent data (June 2026), DRMAW shows a operating income of $-8.6M. That compares with $-11M in the prior-year period — up 18.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, DRMAW's operating income is now $-8.6M (was $-11M) — a 18.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Dermata Therapeutics- Warrants (13/08/2026) is outperforming or lagging.

Tracking DRMAW's operating income over time shows whether Dermata Therapeutics- Warrants (13/08/2026) is scaling, shrinking, or reshaping that part of the business. The current reading is $-8.6M That compares with $-11M in the prior-year period — up 18.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Dermata Therapeutics- Warrants (13/08/2026)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-8.6M) with ownership activity and broader fundamentals.

Dermata Therapeutics- Warrants (13/08/2026)'s operating income is $-8.6M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.